REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
ROCKVILLE, Md., Aug. 8, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on Thursday, August 15, 2024.
2024年8月8日，馬里蘭州羅克維爾--REGENXBIO公司（納斯達克：regenxbio）今天宣佈，將於2024年8月15日週四參加H.C. Wainwright第四屆年度在線眼科醫療大會。
H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Panel: The Evolving Therapeutic Landscape of AMD
Date/Time: Thursday, August 15, 2024 at 9:00 a.m. EDT
Location: Virtual
H.C. Wainwright第四屆年度在線眼科醫療大會
專題討論：AMD的不斷髮展的治療手段
日期/時間：2024年8月15日週四美國東部時間上午9:00
地點：虛擬
A live webcast of the panel can be accessed in the Investors section of REGENXBIO's website at . An archived replay of the webcast will be available for approximately 30 days following the presentation.
可在REGENXBIO網站的投資者部分訪問該專題研討會的實時網絡直播，演示結束後約30天內可以查看其歸檔回放。
ABOUT REGENXBIO Inc.
關於REGENXBIO公司
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit .
REGENXBIO是一家領先的臨床階段生物技術公司，旨在通過基因療法的治癒潛力改善人類生活。自2009年成立以來，REGENXBIO開創了AAV Therapeutics的發展，這是一種創新的基因療法藥物類別。REGENXBIO正在推進一系列用於視網膜和罕見疾病的AAV治療，包括ABBV-RGX-314用於治療激素性黃斑變性和糖尿病性視網膜病變，正在與AbbVie合作開發，RGX-202用於Duchenne的治療和RGX-121用於MPS II的治療。REGENXBIO的AAV Therapeutic平台已經治療了成千上萬的患者，包括諾華的ZOLGENSMA，用於治療脊髓性肌萎縮症的兒童。作爲一次性治療，AAV Therapeutic具有改變數百萬人的健康保健方式的潛力。有關更多信息，請訪問 。
Contacts:
聯繫人：
Dana Cormack
Corporate Communications
[email protected]
達納Cormack
企業通訊
[email protected]
Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
[email protected]
投資者：
Chris Brinzey，ICR Westwicke
339-970-2843
[email protected]
SOURCE REGENXBIO Inc.
來源REGENXBIO公司。